Efficacy of rituximab in refractory antisynthetase syndrome

We report the successful use of repeated administration of rituximab in a patient with antisynthetase syndrome refractory to conventional immunosuppressive medications. A literature review revealed that previous experience with rituximab in this condition has been sparse. The rationale for the use of B‐cell depleting therapies in antisynthetase syndrome has been explored in light of the current understanding of the pathogenesis of this condition.